Phcog.Net logo

BROWSE ALL JOURNALS

    SEE ALL 6 JOURNALS
    Phcog.Net JOURNAL OF PHARMACOLOGY AND PHARMACOTHERAPEUTICS Volume 13 · Issue 1 2022 · pp. 5–107
    Search this issue

    Cover: Journal of Pharmacology and Pharmacotherapeutics

    Journal of Pharmacology and Pharmacotherapeutics

    Volume 13, Issue 1

    2022 · pp. 5–107 · 16 articles

    Volume
    13
    Issue
    1
    Published
    2022
    Pages
    5–107
    Articles
    16
    Sections
    4
    ISSN
    ISSN: Print - 0976-500X, Online - 0976-5018
    Journal
    J Pharmacol. Pharmacother.

    In this issue

    Review Article

    1. Review

      Antivitamins: A Silver Lining in the Era of Antimicrobial Resistance

      Nayesha Mahwish, Laxminarayana Kurady Bairy, Sureshkumar Srinivasamurthy

      pp. 5–13 · DOI: 10.1177/0976500X221080378 · Published 2022

      Antivitamins are compounds that negate the biological effects of vitamins. They have been successfully exploited for the development of various classes of drugs. In the early 19th century, the antifolate prontosil was de

    Case Report

    1. Article

      Xylometazoline Induced Isolated Left Medial Cerebellar Peduncle Infarct: A Rare Case Report

      Ankit Bhardwaj, Shoma Mukherjee, Vandana Roy

      pp. 102–107 · DOI: 10.1177/0976500X221080224 · Published 2022

      Xylometazoline, a sympathomimetic available as over the counter drug, acts as a nasal decongestant and has been reported as an independent risk factor for hemorrhagic and ischemic stroke. The chronic use of xylometazolin

    2. Article

      Bullous Drug Reaction with Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

      K. Geetha, Puja Puja

      pp. 99–101 · DOI: 10.1177/0976500X221080309 · Published 2022

      Hypoglycemic drugs in the dipeptidyl peptidase-4 (DPP-4) inhibitor class are used as a second-line treatment for type 2 diabetes mellitus. With DPP-4 inhibitors, there have been a few reports of cutaneous side effects su

    Research Article

    1. Article

      Systematic Review and Meta-Analysis Comparing the Safety of Natalizumab, Ocrelizumab, and Alemtuzumab in Treating Relapsing–Remitting, Primary Progressive, and Secondary Progressive Multiple Sclerosis

      Pooja Raina, Somnath Basu, Ramesh K Goyal, Pravat K Sahoo, Rajani Mathur

      pp. 14–23 · DOI: 10.1177/0976500X221080225 · Published 2022

      Three monoclonal antibodies—natalizumab (NTZ), ocrelizumab (OCR), and alemtuzumab (ALM)—are the mainstays for the treatment of both relapsing and progressive forms of multiple sclerosis (MS). Here, their safety in patien

    2. Article

      Review of the Long-Term Effect of the Atypical Antipsychotic Medication on the Bone Mineral Density of the Pediatric Patient with Consideration of Autism Spectrum Disorder

      Wisam Al Jumaili, Ashraf Muzwagi

      pp. 24–30 · DOI: 10.1177/0976500X221080296 · Published 2022

      Objectives: To shed some light on the understudied complication of chronic prolonged exposure to antipsychotics (AP) in children with consideration to with autism spectrum disorder (ASD). Methods: We electronically searc

    3. Article

      The Role of Olfactory System in the Etiogenesis of Parkinson’s Diseases: An Overview

      Jiju Narayanan Avanipully, Dithu Thekkekkara, Sahyadri M, Vipan K. Parihar, Santhepete Nanjundaiah Manjula

      pp. 31–39 · DOI: 10.1177/0976500X221085802 · Published 2022

      Parkinson’s disease (PD) mainly affects the dopaminergic neuronal networks of the substantia nigra, which leads to both motor and nonmotor symptoms of the disease. Based on the reports from the previous studies, 95% of t

    4. Article

      COVID-19 and Substance Use: A Scientometric Assessment of Global Publications During 2020 and 2021

      Sandeep Grover, B.M. Gupta, K.K. Mueen Ahmed

      pp. 40–47 · DOI: 10.1177/0976500X221080393 · Published 2022

      Aim: This study aimed to assess the characteristics and trends of research on substance use and COVID-19. Methods: Keywords related to “Covid-19” and “Substance Use” were used in a search query formulated for the Scopus

    5. Article

      Ethnopharmacology Research: A Scientometric Assessment of Indian Publications During 2011 to 2020

      Chaman Sab M., Mallikarjun Kappi, K.K. Mueen Ahmed

      pp. 48–58 · DOI: 10.1177/0976500X221082839 · Published 2022

      The current research has been conducted to study the ethnopharmacology research output in the past 10 years (2011–2020) after using Web of Science (WoS) database. The present study has used WoS database to collect the et

    6. Article

      Comparison Between Dexamethasone and Fentanyl as an Adjuvant to Bupivacaine and Lignocaine in Supraclavicular Brachial Plexus Block for Upper Limb Surgery

      Shilpa Sarang Kore, Smita Bhau Ubhe, Fathima Fasil

      pp. 59–65 · DOI: 10.1177/0976500X221085803 · Published 2022

      Objective: To compare the effects of dexamethasone and fentanyl when added to a mixture of bupivacaine and lignocaine in supraclavicular blocks in patients undergoing forearm surgeries. Methods: Sixty-six patients aged b

    7. Article

      Predictors of Pharmacotherapy and Quality of Life Among Patients With Diabetic Foot Syndrome: A Cross-Sectional Study from a Tertiary Care Hospital in India

      E. Pasangha, B. George, K. B. Bhuvana, D. Padmini

      pp. 66–71 · DOI: 10.1177/0976500X221080291 · Published 2022

      Objective: To assess the patterns and predictors of pharmacotherapy and QOL in DFS patients in an Indian tertiary care hospital. Methods: A cross-sectional study was conducted among inpatients with DFS. Data on sociodemo

    8. Article

      Development of Physiologically Based Pharmacokinetic Model and Assessment of the Impact of Renal Underdevelopment in Preterm Infants on the Pharmacokinetics of Aminophylline

      Hari Prabhath Tummala, Rachana Balusu, Sahithi Thotakura, Achyuth Kumar Pasnoor, Arun Prasath Raju, Shivakumar Mahadeva Lal, Leslie Edwards Lewis, Surulivelrajan Mallayasamy

      pp. 72–78 · DOI: 10.1177/0976500X221080209 · Published 2022

      Objective: To develop a physiologically based pharmacokinetic (PBPK) model for individualization of the dosing regimen considering the physiological requirements of these preterm neonates. Methods: The study comprised pr

    9. Article

      A Randomized Double-Blind Comparative Study of Efficacy and Safety Between Low-Dose Etoricoxib and Ibuprofen Coadministered with Low-Dose Paracetamol for Dental Pain

      Kothari Saroj, Bansal Haresh, Paharia Yogendra

      pp. 79–84 · DOI: 10.1177/0976500X221080380 · Published 2022

      Objective: To study the safety and efficacy of low-dose etoricoxib and low-dose paracetamol versus ibuprofen and low-dose paracetamol treatments in patients who experienced acute pain after tooth extraction. Methods: A t

    10. Article

      Study of Hemodynamic Effects of Preoperative Single-Bolus Dexmedetomidine in Elective Laparoscopic Surgeries

      Fathima Fasil, Girish Saundattikar, Reema Hemant Jawale, Naveen Kumar J.

      pp. 85–91 · DOI: 10.1177/0976500X221080390 · Published 2022

      Objective: To observe the hemodynamic effects of a single bolus dose of dexmedetomidine in patients undergoing elective laparoscopic surgeries. Methods: A total of 60 adult patients were randomized into two groups of 30

    Research Letter

    1. Article

      Availability of the Essential Medicines is Community Pharmacies: A Cross-Sectional Study

      Pallavi Jha, Sneha Ambwani, Surjit Singh, Pankaj Bhardwaj, Shobhan Babu Varthya, Jaykaran Charan

      pp. 92–94 · DOI: 10.1177/0976500X221080370 · Published 2022

      World Health Organization (WHO) defines essential drugs or medicines as “those drugs that satisfy the healthcare needs of majority of the population; they should therefore be available at all times in adequate amounts an

    2. Article

      Can We Use Terminalia Arjuna (Roxb.) Wight and Arn in Place of Novel Oral Anticoagulants (NOACs) in Post-COVID-19 Cardiac Conditions?

      Shridhar Dwivedi, Vinod Sharma, C. R. Patil

      pp. 95–96 · DOI: 10.1177/0976500X221080202 · Published 2022

      COVID-19 is known to cause several cardiac disorders such as pancarditis, coronary artery disease (CAD), arrhythmias, cardiomyopathy, and stroke during and after the active stage of the COVID-19 infection, even when the

    3. Article

      Physician Preferences for Olanzapine Standard Oral Tablets and Orally Disintegrating Tablets: A Cross-Sectional Survey

      Hardik Gandhi

      pp. 97–98 · DOI: 10.1177/0976500X221080392 · Published 2022

      Olanzapine, a second-generation antipsychotic, is indicated for the treatment of schizophrenia and bipolar disorder.1 Oral formulations of olanzapine include standard oral tablets (SOT) and orally disintegrating tablets